Les Brail, Ph.D.
About Les Brail, Ph.D.
Les Brail, Ph.D., is a seasoned professional in early clinical development, currently serving as the Senior Vice President at an undisclosed company.
Les Brail, Ph.D. Senior Vice President of Early Clinical Development
Les Brail, Ph.D., serves as the Senior Vice President of Early Clinical Development. In this role, he oversees the early stages of clinical trials, including protocol development, patient recruitment, and data analysis. His work ensures that innovative therapies move efficiently from the lab to clinical testing phases, laying the groundwork for future medical advancements.
Ph.D. in Medical Biophysics from the University of Toronto
Les Brail earned his Ph.D. in Medical Biophysics from the University of Toronto. This advanced education provided him with a strong foundation in the principles of biophysics as applied to medicine, equipping him with the expertise to contribute effectively to clinical research and drug development processes.
Leadership in Clinical Development at Neon Therapeutics
Les Brail previously led the clinical development of personalized neoantigen vaccine programs at Neon Therapeutics. His responsibilities included designing and implementing clinical trials to evaluate the safety and efficacy of these personalized medicines, aiming at harnessing the patient's immune system to target and eliminate cancer cells.
Program Team Leader of IPI-549 at Infinity Pharmaceuticals
At Infinity Pharmaceuticals, Les Brail served as the Program Team Leader of IPI-549, a PI3K-gamma inhibitor. He directed the clinical program, focusing on its therapeutic potential and effectiveness in treating various cancer types, and orchestrated cross-functional teams to expedite the drug's development.
Early Phase Oncology Drug Development at Eli Lilly and Company
Les Brail began his career at Eli Lilly and Company in their early phase Oncology drug development group. This role involved the initial phases of clinical trials, from conceptualization through initial proof of concept, contributing to the foundation of his expertise in oncology drug development.